Infectious Diseases Molecular Diagnostics Market Report 2022 to 2032 Trends, Drivers, Strategies

BySanket Badgujar
Market Research

The Global Infectious Disease Molecular Diagnostics Market was valued at US$ 34 Bn in 2021 and is expected to reach US$ 53 Bn by 2032, finds Future Market Insights (FMI) in a recent market survey. As per the findings of the report, it is projected that revenue through the Polymerase Chain Reaction (PCR) segment in the Infectious Disease Molecular Diagnostics Market will grow at 5.2% CAGR during the forecast period.

For the detection of genetic polymorphisms, hereditary diseases, somatic mutations, including cancer, and the presence of viral or microbial infections, a qualitative result of a PCR inquiry may be necessary. In order to determine a pathogen’s “titer,” the number of infected or changed cells in a tissue, and the concentration of certain mRNAs, quantitative PCR is becoming more and more necessary. Polymerase Chain Reaction is used in medicine for a variety of purposes, such as tissue typing for organ and tissue transplants.

The United States will hold the largest share of the market throughout the Analysis Period

From 2022 to 2032, the Infectious Disease Molecular Diagnostics Market is estimated to develop at a CAGR of 4.3% in the United States. According to the article “Chronic Diseases in America” from the National Center for Chronic Disease Prevention and Health Promotion, which was updated in January 2021, 6 out of 10 adults in the US have a chronic disease, and 4 out of 10 people have two or more chronic diseases.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/REP-GB-15835

According to the American Cancer Society, there will be 1.7 Mn new cases of cancer this year and more than 606 thousand deaths from cancer. Because of the rising cancer incidence and growing public awareness of the value of early cancer detection, it is therefore projected that over the forecast period, the usage of molecular diagnostics will increase. Becton Dickinson and Euroclone announced in February 2019 a development and global distribution partnership for molecular testing in Mexico to discover new sexually transmitted illnesses. Future market growth is anticipated to grow as a result of increasing disease rates and technological advancements in North America.

Infectious Disease Molecular Diagnostics Market: Competition Insights

At present, many diagnostics firms that were under-represented in this area have sought partners or acquisitions to gain exposure, reflecting the growing interest in personalized medicine. The key companies operating in the market include F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Abbott Laboratories, bioMérieux SA, QIAGEN N.V., Myriad Genetics, Inc., Siemens Healthineers AG, Danaher Corporation, Illumina, Inc., Becton Dickinson and Company, Grifols, S.A., Quidel Corporation, Agilent Technologies, Inc., DiaSorin S.p.a. (Italy), Exact Sciences Corporation, Genetic Signatures, MDx Health, Biocartis NV, TBG Diagnostics Limited, HTG Molecular Diagnostics, Inc., Vela Diagnostics, Amoy Diagnostics Co., Ltd., ELITechGroup, Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, Abacus Diagnostica Oy, and geneOmbio Technologies Pvt. Ltd.

Some of the recent developments by key providers of the Infectious Disease Molecular Diagnostics are as follows:

  • In September 2021, F. Hoffmann-La Roche Ltd. announced the acquisition of TIB Molbiol to increase the breadth of infectious illness assays in its PCR test line.
  • In June 2021 Verogen and QIAGEN N.V. collaborated to increase the range of NGS technologies available.
  • In June 2021 Mobidiag Oy, a pioneer in acute care molecular diagnostic testing, was purchased by Hologic, Inc. The product offering for molecular diagnostics at Hologic will be boosted by this acquisition.
  • In November 2020, an additional FDA approval was given to Hologic, Inc. for the AptimaHIV-1 Quant Dx Assay’s use in assisting with HIV infection diagnosis.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the infectious disease molecular diagnostics market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights by Product Type (Instruments, Reagents, and Other Product Types), by Test Location (Point-of-Care, Self-test or Over the Counter, and Central Laboratories), By Technology (Polymerase Chain Reaction, In Situ Hybridization, Isothermal, Nucleic Acid Amplification Technology, Chips and Microarrays, Mass Spectrometry, Sequencing, and Other Technologies), by End-Use (Hospitals, Clinics, Diagnostics Laboratories, Research Institutes), by Application (Respiratory Diseases, Tuberculosis, Meningitis, Gastrointestinal Tract Infections, HPV, Sexually Transmitted Infections, Sepsis, Drug Resistance Diseases, Other Infectious Diseases), across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Key Segments Covered in Infectious Disease Molecular Diagnostics Market Survey

By Technology:

  • Polymerase chain reaction (PCR)
  • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • Others

By Product Type:

  • Instruments
  • Reagents
  • Services

By End Use:

  • Hospitals
  • Clinics
  • Diagnostics Laboratories
  • Research Institutes

By Application:

  • Respiratory Diseases
  • Tuberculosis
  • Meningitis
  • Gastrointestinal Tract Infections
  • HPV
  • Sexually Transmitted Infections
  • Sepsis
  • Drug Resistance Diseases
  • Other Infectious Diseases

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa